Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (3427)	6/12/2003 11:20:44 AM
From: Icebrg	Read Replies (2) \| Respond to of 37387

Crossy >>But there's the other biotech (former NEOT) products that SPPI is pursuing enabling further upside>> Satraplatin might well offer some positive surprises if GPC Biotech manages to get it approved. An oral platinum-based drug should have a substantial niche to fill. And initial results from the Eoquin-study are interesting. Although I believe they will have to wait for relapses to set in, before they can say how effective the drug is in that setting. The positive thing is that cancer drugs is something that Raj and Luigi have been working with for most of their lives. Most of the time at BMY. So they should have a fairly good idea about what they are doing. As this is a rather unknown company, I am a little bit curious how you found your way to them. May I ask? Erik